AR056306A1 - FORMA CRISTALINA ORTORRoMBICA DEL MALEATO DE ASENAPINA , COMPOSICIONES FARMACÉUTICAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MENTALES - Google Patents

FORMA CRISTALINA ORTORRoMBICA DEL MALEATO DE ASENAPINA , COMPOSICIONES FARMACÉUTICAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MENTALES

Info

Publication number
AR056306A1
AR056306A1 ARP060101358A ARP060101358A AR056306A1 AR 056306 A1 AR056306 A1 AR 056306A1 AR P060101358 A ARP060101358 A AR P060101358A AR P060101358 A ARP060101358 A AR P060101358A AR 056306 A1 AR056306 A1 AR 056306A1
Authority
AR
Argentina
Prior art keywords
orthrombemic
treatment
pharmaceutical compositions
crystal form
mental disorders
Prior art date
Application number
ARP060101358A
Other languages
English (en)
Inventor
Gerhardus Johannes Heeres
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36617328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056306(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organon Nv filed Critical Organon Nv
Publication of AR056306A1 publication Critical patent/AR056306A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

REIVINDICACIoN 1.- Un compuesto caracterizado porque es (Z)-2-butenodioato de trans-5-cloro-2,3,3a,12b,tetrahidro-2-metil-1H-dibenz[2,3:6,7] oxepino [4,5-c] pirrol ortorrombico.
ARP060101358A 2005-04-07 2006-04-06 FORMA CRISTALINA ORTORRoMBICA DEL MALEATO DE ASENAPINA , COMPOSICIONES FARMACÉUTICAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MENTALES AR056306A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05102742 2005-04-07
EP05102969 2005-04-14

Publications (1)

Publication Number Publication Date
AR056306A1 true AR056306A1 (es) 2007-10-03

Family

ID=36617328

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101358A AR056306A1 (es) 2005-04-07 2006-04-06 FORMA CRISTALINA ORTORRoMBICA DEL MALEATO DE ASENAPINA , COMPOSICIONES FARMACÉUTICAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MENTALES

Country Status (31)

Country Link
EP (2) EP1917267B1 (es)
JP (1) JP5058151B2 (es)
KR (1) KR101422843B1 (es)
AR (1) AR056306A1 (es)
AT (2) ATE418556T1 (es)
AU (1) AU2006231617B2 (es)
BR (1) BRPI0609741A8 (es)
CA (1) CA2603509C (es)
CY (2) CY1106902T1 (es)
DE (2) DE602006004463D1 (es)
DK (2) DK1917267T3 (es)
DO (1) DOP2006000082A (es)
ES (2) ES2293626T3 (es)
GT (1) GT200600135A (es)
HN (1) HN2006014095A (es)
HR (1) HRP20070429T3 (es)
IL (1) IL186355A (es)
MX (1) MX2007012445A (es)
MY (1) MY137969A (es)
NO (1) NO340520B1 (es)
NZ (1) NZ562124A (es)
PE (1) PE20061311A1 (es)
PL (2) PL1710245T3 (es)
PT (2) PT1917267E (es)
RS (1) RS50532B (es)
RU (1) RU2405786C2 (es)
SI (2) SI1917267T1 (es)
SV (1) SV2006002473A (es)
TW (1) TWI364423B (es)
UY (1) UY29459A1 (es)
WO (1) WO2006106135A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667668A1 (en) * 2006-10-06 2008-04-10 N.V. Organon Amorphous asenapine and processes for preparing same
AR077225A1 (es) * 2009-06-24 2011-08-10 Organon Nv Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza
CA2802990A1 (en) 2010-06-18 2011-12-22 Dr. Reddy's Laboratories Ltd. Asenapine maleate
WO2012066565A2 (en) * 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
ITMI20110734A1 (it) * 2011-05-02 2012-11-03 Olon Spa Sali cristallini di asenapina
EP2524920A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Asenapine Hydrochloride Salt Forms
EP2524919A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
EP2524921A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Salts of Asenapine
JP6014656B2 (ja) * 2011-05-18 2016-10-25 ラビラトリオス レスビ エス エレ 化合物の多形体
US9533994B2 (en) 2011-05-18 2017-01-03 Laboratorios Lesvi S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
EP2572703A1 (en) 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
JP6005742B2 (ja) * 2012-07-26 2016-10-12 久光製薬株式会社 貼付剤
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
WO2014090386A1 (en) 2012-12-11 2014-06-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
US10786520B2 (en) 2015-09-02 2020-09-29 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
BR112019012573A2 (pt) 2016-12-20 2019-11-19 Lts Lohmann Therapie Systeme Ag sistema terapêutico transdérmico que contém asenapina e polissiloxano ou poli-isobutileno
WO2018115001A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
KR100330942B1 (ko) * 1994-03-02 2002-11-16 악조 노벨 엔.브이. 설하또는협측투여용약학조성물
WO1999032108A1 (en) * 1997-12-19 1999-07-01 Akzo Nobel N.V. Org-5222 in the treatment of depression
TWI327915B (en) * 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight

Also Published As

Publication number Publication date
PT1710245E (pt) 2007-10-03
BRPI0609741A8 (pt) 2018-03-13
AU2006231617A1 (en) 2006-10-12
JP5058151B2 (ja) 2012-10-24
EP1710245A1 (en) 2006-10-11
ATE370954T1 (de) 2007-09-15
ATE418556T1 (de) 2009-01-15
CY1108742T1 (el) 2014-04-09
DE602006004463D1 (de) 2009-02-05
SI1917267T1 (sl) 2009-04-30
RU2405786C2 (ru) 2010-12-10
KR101422843B1 (ko) 2014-07-24
BRPI0609741A2 (pt) 2010-04-27
ES2318742T3 (es) 2009-05-01
KR20080005253A (ko) 2008-01-10
CA2603509A1 (en) 2006-10-12
DK1710245T3 (da) 2007-12-03
SV2006002473A (es) 2009-11-24
EP1917267A1 (en) 2008-05-07
EP1710245B1 (en) 2007-08-22
AU2006231617B2 (en) 2010-06-03
PE20061311A1 (es) 2007-02-09
RU2007141198A (ru) 2009-05-20
DE602006000080T2 (de) 2008-05-15
ES2293626T3 (es) 2008-03-16
NO20075142L (no) 2007-11-05
DK1917267T3 (da) 2009-04-14
TW200722428A (en) 2007-06-16
MY137969A (en) 2009-04-30
DOP2006000082A (es) 2006-11-30
CA2603509C (en) 2013-12-03
DE602006000080D1 (de) 2007-10-04
RS50532B (sr) 2010-05-07
EP1917267B1 (en) 2008-12-24
PL1917267T3 (pl) 2009-06-30
JP2008534656A (ja) 2008-08-28
NO340520B1 (no) 2017-05-02
HN2006014095A (es) 2010-08-19
WO2006106135A1 (en) 2006-10-12
HRP20070429T3 (en) 2007-11-30
IL186355A0 (en) 2008-01-20
UY29459A1 (es) 2006-11-30
TWI364423B (en) 2012-05-21
CY1106902T1 (el) 2012-09-26
IL186355A (en) 2016-05-31
MX2007012445A (es) 2007-11-07
GT200600135A (es) 2006-11-07
PL1710245T3 (pl) 2008-01-31
SI1710245T1 (sl) 2007-12-31
PT1917267E (pt) 2009-02-04
NZ562124A (en) 2010-07-30

Similar Documents

Publication Publication Date Title
AR056306A1 (es) FORMA CRISTALINA ORTORRoMBICA DEL MALEATO DE ASENAPINA , COMPOSICIONES FARMACÉUTICAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MENTALES
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
CL2007001731A1 (es) Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
CL2007001732A1 (es) Compuestos derivados de imidazo[1,5-a]pirimidina; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
CR8642A (es) Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
CL2007001733A1 (es) Compuestos derivados de imidazol condensado con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir un trastorno asociado con el deterioro cognitivo, la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
ZA201100526B (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
MX2009003125A (es) Tiazol pirazolopirimidinas como antagonistas de receptor de crf1.
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
BRPI0410905A (pt) inibidores de p-38
DE602004025504D1 (de) Bicyclische heterocyclische p-38-kinase-inhibitoren
UY29099A1 (es) Fenilaminotiazoles sustituidos y su uso
CL2009000697A1 (es) Compuestos derivados de 2-heteroaril-6-fenil-imidazol [1,2-a]piridinas sustituidas; moduladores de receptores not; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de cancer, inflamacion, enfermedades neurodegenerativas, psiquiatricas, epilepsia, entre otras.
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
CL2008000981A1 (es) Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu
AR057239A1 (es) Inmunoglobulinas
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
GT200500266A (es) Nuevos derivados de pirimidina y su uso
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.

Legal Events

Date Code Title Description
FC Refusal